Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN )

10.39 +0.46 (+4.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 662,751
Open 10.68
Bid (Size) 10.08 (1)
Ask (Size) 10.93 (4)
Prev. Close 9.930
Today's Range 10.35 - 10.96
52wk Range 9.780 - 20.70
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
From UroGen Pharma Ltd.
Via Business Wire
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-2.90%
-2.90%
1 Month
-8.05%
-8.05%
3 Month
-15.25%
-15.25%
6 Month
-39.66%
-39.66%
1 Year
-29.18%
-29.18%

More News

Read More
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
From UroGen Pharma Ltd.
Via Business Wire
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
From UroGen Pharma Ltd.
Via Business Wire
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
UroGen Appoints Chris Degnan as Chief Financial Officer
From UroGen Pharma Ltd.
Via Business Wire
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From UroGen Pharma Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.